Apellis Pharmaceuticals Inc (FRA:1JK)
€ 36.59 -0.37 (-1%) Market Cap: 4.53 Bil Enterprise Value: 4.33 Bil PE Ratio: 0 PB Ratio: 18.22 GF Score: 49/100

Q4 2020 Apellis Pharmaceuticals Inc Earnings Call Transcript

Feb 25, 2021 / 09:30PM GMT
Release Date Price: €37.6
Operator

Good afternoon. My name is Valerie, and I will be your conference operator today. At this time, I would like to welcome everyone to Apellis Pharmaceuticals Fourth Quarter and Full Year 2020 Fiscal Results Conference Call. Today's call is being recorded and a replay will available at apellis.com. I would now like to turn the call over to Tracy Vineis, Vice President of Communications at Apellis.

Tracy Vineis
Apellis Pharmaceuticals, Inc. - VP of Corporate Affairs

Thank you, Valerie. Good afternoon, and thank you for joining us today to discuss Apellis' fourth quarter and full year 2020 financial results. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Chief Medical Officer, Dr. Federico Grossi; Chief Commercial Officer, Adam Townsend; and Chief Financial Officer, Timothy Sullivan.

Before we begin, I would like to point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot